EA201700038A1 - Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств - Google Patents

Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств

Info

Publication number
EA201700038A1
EA201700038A1 EA201700038A EA201700038A EA201700038A1 EA 201700038 A1 EA201700038 A1 EA 201700038A1 EA 201700038 A EA201700038 A EA 201700038A EA 201700038 A EA201700038 A EA 201700038A EA 201700038 A1 EA201700038 A1 EA 201700038A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazolo
treatment
oxatriazoly
olate
application
Prior art date
Application number
EA201700038A
Other languages
English (en)
Other versions
EA032337B1 (ru
Inventor
Юрий Владимирович ХМЕЛЬЩИКОВ
Дмитрий Сергеевич НОСКОВ
Original Assignee
Общество С Ограниченной Ответственностью "Консорциум-Пик"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Консорциум-Пик" filed Critical Общество С Ограниченной Ответственностью "Консорциум-Пик"
Publication of EA201700038A1 publication Critical patent/EA201700038A1/ru
Publication of EA032337B1 publication Critical patent/EA032337B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств Изобретение относится к химико-фармацевтической промышленности, в частности, к созданию нового средства для лечения сексуальных расстройств, и может быть использовано в биохимии, физиологии и медицине.
EA201700038A 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств EA032337B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014127279/15A RU2600845C2 (ru) 2014-07-04 2014-07-04 Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
PCT/RU2015/000413 WO2016003327A1 (ru) 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств

Publications (2)

Publication Number Publication Date
EA201700038A1 true EA201700038A1 (ru) 2017-07-31
EA032337B1 EA032337B1 (ru) 2019-05-31

Family

ID=55019709

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700038A EA032337B1 (ru) 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств

Country Status (7)

Country Link
US (1) US9795593B2 (ru)
EP (1) EP3165223B1 (ru)
EA (1) EA032337B1 (ru)
ES (1) ES2747995T3 (ru)
PL (1) PL3165223T3 (ru)
RU (1) RU2600845C2 (ru)
WO (1) WO2016003327A1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3911668A1 (de) 1989-04-10 1990-10-11 Cassella Ag Substituierte 1.2.3.4-oxatriazolium-5-olate, verfahren zu ihrer herstellung und ihre verwendung
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
WO2005023189A2 (en) 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
JP2008520578A (ja) 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2121640A1 (en) 2007-01-18 2009-11-25 NeuroSearch AS Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
RU2351328C1 (ru) 2007-08-02 2009-04-10 Общество с ограниченной ответственнотью "Консорциум-ПИК" (ООО "Консорциум-ПИК") Гипотензивное средство 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата длительного действия
JP5819951B2 (ja) 2010-06-25 2015-11-24 ホーファグ リサーチ （アイピー） ピーアールイー リミテッド セクシャルウェルネスを改善するための組成物
KR101189108B1 (ko) 2011-12-29 2012-10-10 재단법인 전라남도생물산업진흥재단 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물

Also Published As

Publication number Publication date
WO2016003327A1 (ru) 2016-01-07
RU2014127279A (ru) 2016-01-27
EA032337B1 (ru) 2019-05-31
WO2016003327A9 (ru) 2016-02-11
EP3165223A4 (en) 2017-07-26
EP3165223A1 (en) 2017-05-10
PL3165223T3 (pl) 2020-01-31
RU2600845C2 (ru) 2016-10-27
US9795593B2 (en) 2017-10-24
EP3165223B1 (en) 2019-06-26
US20170202809A1 (en) 2017-07-20
ES2747995T3 (es) 2020-03-12

Similar Documents

Publication Publication Date Title
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
TWD187898S (zh) 按摩器
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EA201790998A1 (ru) Иммуннорегуляторные агенты
CL2017000806A1 (es) Compuestos anti-tnf
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790785A1 (ru) Производные тетрагидроизохинолина
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201891609A1 (ru) Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM